Diagnosis of Alzheimer's disease (AD) is often difficult, especially early in the disease process at the stage of mild cognitive impairment (MCI). Yet, it is at this stage that treatment is most likely to be effective, so there would be great advantages in improving the diagnosis process. We describe and test a machine learning approach for personalized and cost-effective diagnosis of AD. It uses locally weighted learning to tailor a classifier model to each patient and computes the sequence of biomarkers most informative or cost-effective to diagnose patients. Using ADNI data, we classified AD versus controls and MCI patients who progressed to AD within a year, against those who did not. The approach performed similarly to considering all ...
Alzheimer disease (AD) is one of the most common degenerative illnesses of the elderly worldwide. It...
One of the current challenges in the field of Alzheimer's disease (AD) is to identify patients with ...
BackgroundPredicting clinical course of cognitive decline can boost clinical trials' power and impro...
Alzheimer\u27s Disease (AD) is a neurodegenerative disease that causes complications with thinking c...
Alzheimer’s disease (AD) is a neurodegenerative disease with typical clinical symptoms in the form o...
Alzheimers Disease (AD) is believed to be the most widely recognized reason for dementia and it is a...
Alzheimer’s disease (AD) progresses relentlessly from the preclinical to the dementia stage. The pro...
Alzheimer’s disease (AD) is the most common form of dementia. AD begins slowly, where it first invol...
Treball de fi de grau en Sistemes AudiovisualsTutors. Gemma Piella Fenoy, Gerard Martí JuanIt is est...
Alzheimer’s disease (AD) is an insidious disorder in which pathology may develop decades before outw...
There is a need for objective tools to help clinicians to diagnose Alzheimer's Disease (AD) early an...
With an aging population and the increased burden and economic cost of dementia on the community, co...
Recent research in computational engineering have evidenced the design and development numerous inte...
[[abstract]]Alzheimer's disease (AD) is a neurodegenerative disorder with an insidious onset and irr...
Brain pathological changes linked with Alzheimer's disease (AD) can be measured with Neuroimaging. I...
Alzheimer disease (AD) is one of the most common degenerative illnesses of the elderly worldwide. It...
One of the current challenges in the field of Alzheimer's disease (AD) is to identify patients with ...
BackgroundPredicting clinical course of cognitive decline can boost clinical trials' power and impro...
Alzheimer\u27s Disease (AD) is a neurodegenerative disease that causes complications with thinking c...
Alzheimer’s disease (AD) is a neurodegenerative disease with typical clinical symptoms in the form o...
Alzheimers Disease (AD) is believed to be the most widely recognized reason for dementia and it is a...
Alzheimer’s disease (AD) progresses relentlessly from the preclinical to the dementia stage. The pro...
Alzheimer’s disease (AD) is the most common form of dementia. AD begins slowly, where it first invol...
Treball de fi de grau en Sistemes AudiovisualsTutors. Gemma Piella Fenoy, Gerard Martí JuanIt is est...
Alzheimer’s disease (AD) is an insidious disorder in which pathology may develop decades before outw...
There is a need for objective tools to help clinicians to diagnose Alzheimer's Disease (AD) early an...
With an aging population and the increased burden and economic cost of dementia on the community, co...
Recent research in computational engineering have evidenced the design and development numerous inte...
[[abstract]]Alzheimer's disease (AD) is a neurodegenerative disorder with an insidious onset and irr...
Brain pathological changes linked with Alzheimer's disease (AD) can be measured with Neuroimaging. I...
Alzheimer disease (AD) is one of the most common degenerative illnesses of the elderly worldwide. It...
One of the current challenges in the field of Alzheimer's disease (AD) is to identify patients with ...
BackgroundPredicting clinical course of cognitive decline can boost clinical trials' power and impro...